Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Editas Medicine Inc (NASDAQ: EDIT) was $3.08 for the day, up 2.33% from the previous closing price of $3.01. In other words, the price has increased by $2.33 from its previous closing price. On the day, 6.35 million shares were traded. EDIT stock price reached its highest trading level at $3.365 during the session, while it also had its lowest trading level at $2.95.
Ratios:
Our analysis of EDIT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 4.05 whereas as Long-Term Debt/Eq ratio is at 3.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 03 ’25 when Burkly Linda sold 710 shares for $2.60 per share. The transaction valued at 1,843 led to the insider holds 69,490 shares of the business.
Parison Amy sold 458 shares of EDIT for $1,189 on Sep 03 ’25. The SVP, Chief Financial Officer now owns 16,369 shares after completing the transaction at $2.60 per share. On Sep 03 ’25, another insider, O’Neill Gilmore Neil, who serves as the CEO of the company, sold 5,592 shares for $2.60 each. As a result, the insider received 14,517 and left with 274,690 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 276954080 and an Enterprise Value of 119588104. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.12 while its Price-to-Book (P/B) ratio in mrq is 14.03. Its current Enterprise Value per Revenue stands at 3.074 whereas that against EBITDA is -0.776.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.24, which has changed by 0.06944442 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.54, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -4.51%, while the 200-Day Moving Average is calculated to be 39.63%.
Shares Statistics:
EDIT traded an average of 2.38M shares per day over the past three months and 3059400 shares per day over the past ten days. A total of 89.92M shares are outstanding, with a floating share count of 89.37M. Insiders hold about 0.62% of the company’s shares, while institutions hold 47.29% stake in the company. Shares short for EDIT as of 1760486400 were 7619416 with a Short Ratio of 3.20, compared to 1757894400 on 7561998. Therefore, it implies a Short% of Shares Outstanding of 7619416 and a Short% of Float of 8.49.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.26, with high estimates of $0.11 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.68 and -$2.22 for the fiscal current year, implying an average EPS of -$2.0. EPS for the following year is -$0.93, with 7.0 analysts recommending between -$0.63 and -$1.18.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 12 analysts. It ranges from a high estimate of $25M to a low estimate of $500k. As of . The current estimate, Editas Medicine Inc’s year-ago sales were $61k
A total of 12 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $55.74M, while the lowest revenue estimate was $9.2M, resulting in an average revenue estimate of $20.57M. In the same quarter a year ago, actual revenue was $32.31M
